白血病细胞CD56抗原表达与急性髓系白血病患者预后的关系

doi:10.13481/j.1671-587x.20160218

Abstract

Abstract:

Objective: To investigate the expression of CD56 antigen in leukemia cells of the patients with acute myeloid leukemia (AML) and its relationship with the prognosis of AML, and to clarify the role of CD56 antigen expression in predicting the prognosis of the AML patients.Methods: 171 AML (non-M3) patients aged from 14 to 60 years old, who received a IA Regimen as the first time inducing chemotherapy were chosen.Flow cytometric analysis was used to evaluate the CD56 expression in leukemia cells.COX proportional regression analysis was used to select the prognostic factors, and bivariable analysis was used to study the relationship between the positive rate of CD56 and overall survival (OS).The CD56⁺ group(n=52), including CD56≥50% expression group(n=39) and CD56<50% expression group(n=13), and CD56^- group(n=119) were identified by the expression of CD56 antigen.The complete remission rate (CRR), the relapse rate, the median OS, the median disease-free survival (DFS) and the survival rate of patients were compared.Results: The medium OS of the patients in CD56⁺ group (14.2 months) was shorter than that in CD56^- group (39.4 months) (P<0.05).Moreover, the medium OS in CD56≥50% group was shorter than that in CD56<50% group (11.7 months vs 20.3 months, P<0.05).The 1-year and 2-year survival rates of the patients in CD56⁺ group(61.5%, 46.2%) were lower than those in CD56^- group(75.6%, 63.9%)(P<0.05).The 1-year survival rate had no significant difference between CD56≥50% group and CD56<50% group (53.8% vs 84.6%, P>0.05), while the 2-year survival rate in CD56≥50% group was lower than that in CD56<50% group (41.0% vs 61.5%, P<0.05).There were no significant differences of the CRR between CD56⁺ group(76.9%) and CD56^- group (68.9%) as well as CD56≥50% group(58.9%) and CD56<50% group(63.5%) (P>0.05). The relapse rate and first year relapse rate of patients in CD56⁺ group (64.3% and 37.5%) were significantly higher than those in CD56^- group (34.3% and 17.9%) (P<0.05).However, there were no significant differences of the relapse rate and first year relapse rate between CD56≥50% group(75.0% and 42.9%) and CD56<50% group(37.5% and 16.7%) (P>0.05).The DFS in CD56⁺ group was shorter than that in CD56^- group (P<0.05).The same DFS result was also found between CD56≥50% group and CD56<50% group(P<0.05).Conclusion: The expression of CD56 antigen in leukemia cells predicts a bad prognosis in the AML patients, and the higher expression of CD56 indicates the worse prognosis.

Key words: acute myeloid leukemia, CD56, prognosis, overall survival, disease-free survival

CLC Number:

R733.71

LI Qian, LI Jingao, ZHOU Maohua, LIAO Pengjun, PENG Qi, CHEN Jing, CHEN Shaoxian, WEI Shanshan, HUANG Huiting, SHE Miaorong. Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia[J].Journal of Jilin University Medicine Edition, 2016, 42(02): 283-289.

References

[1] Dores GM,Devesa SS,Curtis RE,et al. Acute leukemia incidence and patient survival among children and adults in the United States,2001-2007[J].Blood,2012,119(1):34-43.

[2] Valgardsdottir R,Capitanio C, Texido G,et al.Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56⁺ hematopoietic target cells[J].Exp Hematol,2014,42(12):1013-1021.

[3] Xu S,Li X,Zhang J,et al.Prognostic value of CD56 in patients with acute myeloid leukemia:a meta-analysis[J].J Cancer Res Clin Oncol,2015,141(10):1859-1870.

[4] 魏姗姗,周茂华,李劲高,等.急性髓系白血病患者白血病细胞CD34和CD38抗原的表达及其临床意义[J].吉林大学学报:医学版,2015,41(2):362-367.

[5] 张之南.血液病诊断及疗效标准[M].2版.北京:科学出版社,1998:168-218.

[6] Raspadori D,Damiani D, Lenoci M,et al.CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis[J].Leukemia,2001,15(8):1161-1164.

[7] Junca J,Garcia-Caro M,Granada I,et al.Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis[J].Ann Hematol,2014,93(9):1483-1489.

[8] Iriyama N,Hatta Y,Takeuchi J,et al.CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)[J].Leuk Res,2013,37(9):1021-1026.

[9] Ono T,Takeshita A,Kishimoto Y,et al.Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts[J].Cancer Sci,2014,105(1):97-104.

[10] Mason KD,Juneja SK,Szer J.The immunophenotype of acute myeloid leukemia:is there a relationship with prognosis[J].Blood Rev,2006,20(2):71-82.

[11] Alegretti AP,Bittar CM,Bittencourt R,et al.The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia[J].Rev Bras Hematol Hemoter,2011,33(3):202-206.

[12] Djunic I, Virijevic M,Djurasinovic V,et al.Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia[J].Med Oncol,2012,29(3):2077-2082.

[13] Chang H,Salma F,Yi QL,et al.Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia[J].Leuk Res,2004,28(1):43-48.

[14] Chang H,Brandwein J,Yi QL,et al.Extramedullary infiltrates of AML are associated with CD56 expression,11q23 abnormalities and inferior clinical outcome[J].Leuk Res,2004,28(10):1007-1011.

[15] Jekarl DW,Kim M,Lim J,et al.CD56 antigen expression and hemophagocytosis of leukemic cells in acute myeloid leukemia with t(16;21)(p11;q22)[J].Int J Hematol,2010,92(2):306-313.

[16] Benderra Z,Faussat AM,Sayada L,et al.Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias[J].Clin Cancer Res,2004,10(23):7896-7902.

[17] Montesinos P,Rayón C,Vellenga E,et al.Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens[J].Blood,2011,117(6):1799-1805.

Relationship between CD56 antigen expression in leukemia cells and prognosis of patients with acute myeloid leukemia

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHU Guangwei, ZHENG Wei, HUANG Yongjian, HUA Jin, YANG Shugang, YE Jianxin. Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significance [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1047-1051.
[2]	ZHANG Tao, ZHANG Guoming, YAN Fei, LIU Zheng, HUO Qiang. Values of evaluation of heart rate variability in major adverse cardiac events in patients with acute myocardial infarction after PCI [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 780-785.
[3]	QUAN Xiaoyue, LIU Bailong, LIU Min, DONG Lihua. Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 624-627.
[4]	YU Yunhe, DU Ye, HAN Bing, LI Sijie, SONG Lelian, FAN Zhimin. Observation on curative effects of neoadjuvant chemotherapy for different subtypes of Luminal B breast cancer and analysis on its prognosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 356-362.
[5]	FAN Liwen, FU Tong, GU Lin, WU Di, JIA Hongyao, SONG Dong. Accessory breast cancer: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(02): 412-415.
[6]	SUN Huiying, Du Bo, YU Zhi, LIU Hongquan, YU Hong. Clinical analysis on sudden sensorineural hearing loss complicated with BPPV and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1025-1029.
[7]	SU Junyan, LI Yingjin, XU Changyan. Influence of CD96 and CD71 expressions in surface of leukemia stem cells in therapeutic effects and prognosis of children with acute leukemia [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 776-781.
[8]	YANG Dongyang, LAI Xiaorong, LI Ying, MA Liyu, LUO Gang, LI Zijun, XU Fei, MA Dong. Influence of primary resection and KRAS gene mutation in prognosis of mild symptomatic patients with stage Ⅳ colorectal cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 805-811.
[9]	ZHANG Chengshuai, PAN Cuiliu, GAO Yanan, HAN Bing, ZHANG Zhiru, LI Feng. Meta-analysis on influence of androgen receptor in living conditions of patients with triple-negative breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 73-79.
[10]	HAO Zheng, LIU Nan, WANG Lu, LI Dongyuan, ZHAO Conghai, LIU Weiming, CHEN Zhuo, ZHANG Jinnan. Comparison of clinical effects between hematoma aspiration surgery guided by stereotactic and simple positioning in treatment of patients with medium dose of hypertensive hemorrhage [J]. Journal of Jilin University Medicine Edition, 2017, 43(01): 130-134.
[11]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[12]	GU Sanwei, MA Hongshuang, ZHAO Ling, JIANG Zhenyu. Analysis on clinical characteristics of PM/DM combined with thyroid disease [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 999-1004.
[13]	DING Xianfei, ZHOU Xueliang, DOU Mengmeng, LI Lifeng, GUO Lina, WANG Feng, FAN Qingxia. Expression of mTOR and its relationship with prognosis of breast cancer: a Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(04): 783-788.
[14]	ZAO Hang, WANG XU, LI WEI. Influence of single nucleotide polymorphisms of CDA in prognosis of advanced non-small cell lung cancer patients treated with gemcitabine [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 316-320.
[15]	SHAO Wanting, FU Tong, WU Panpan, WU Di, LI Sijie, ZHENG Chao, FAN Zhimin. Evaluation on efficacy of trastuzumab combined with neoadjuvant chemotherapy in Her-2 positive breast cancer patients and analysis of influencing factors of prognosis [J]. Journal of Jilin University Medicine Edition, 2016, 42(02): 351-357.